Home/Moleac/David Picard

DP

David Picard

CEO

Therapeutic Areas

Neurology Stroke Traumatic Brain Injury Spinal Cord Injury Alzheimer's Disease

Moleac Pipeline

Drug	Indication	Phase
MLC901 (NeuroAiD)	Post‑stroke, Traumatic Brain Injury, Cognitive Decline	Phase 2/3
MLC1501	Post‑stroke motor recovery	Phase 2
ANDROMEDA	Moderate Traumatic Brain Injury	Phase 2
SAMURAI	Mild Traumatic Brain Injury – Cognitive Function	Phase 2
MAESTOSO	Post‑stroke motor deficits	Phase 2

Leadership Team at Moleac

Herve D’Allens

Medical and Marketing Advisor

Senior Medical Advisor

Vice President, Commercial Development

Alliances in China

Vice President, Chief Financial Officer

View full Moleac profile